Ghana: Govt Launches Malaria Vaccine for Children

[VOA] Children in Ghana are starting to get a new vaccine designed to stop malaria. Ghana is the second African country to get the vaccine, which is expected to reduce cases of the mosquito-borne and sometimes fatal disease. But experts caution that other malaria-prevention measures are still necessary.
Source: AllAfrica News: Malaria - Category: Infectious Diseases Source Type: news

Related Links:

Publication date: Available online 13 June 2019Source: CellAuthor(s): Daniel G.W. Alanine, Doris Quinkert, Rasika Kumarasingha, Shahid Mehmood, Francesca R. Donnellan, Nana K. Minkah, Bernadeta Dadonaite, Ababacar Diouf, Francis Galaway, Sarah E. Silk, Abhishek Jamwal, Jennifer M. Marshall, Kazutoyo Miura, Lander Foquet, Sean C. Elias, Geneviève M. Labbé, Alexander D. Douglas, Jing Jin, Ruth O. Payne, Joseph J. IllingworthSummaryThe Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is the leading target for next-generation vaccines against the disease-causing blood-stage of malaria. However...
Source: Cell - Category: Cytology Source Type: research
Conclusions: The ability to label and image non-GMO Plasmodium sporozoites provides the basis for detailed studies on the human skin stage of malaria with potential for in vivo translation. As such, it is an important tool for development of vaccines based on attenuated sporozoites and their route of administration.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
(University of Oxford) Researchers from the University of Oxford, along with partners from five institutions around the world, have identified the human antibodies that prevent the malaria parasite from entering blood cells, which may be key to creating a highly effective malaria vaccination. The results of the study were published today in the journal Cell.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
Vivax malaria is the predominant form of malaria outside Africa, affecting about 14 million people worldwide, with about 2.5 billion people exposed. Development of a Plasmodium vivax vaccine is a priority, and me...
Source: Malaria Journal - Category: Infectious Diseases Authors: Tags: Research Source Type: research
Publication date: Available online 12 June 2019Source: Parasitology InternationalAuthor(s): Vipin Kumar Deo, Yu Inagaki, Elsa Herdiana Murhandarwati, Widya Asmara, Takatsugu Miyazaki, Tatsuya Kato, Enoch Y. ParkAbstractPlasmodium falciparum is a blood protozoan parasite, transmitted by Anopheles mosquitoes vectors, that can cause morbidity and even leads to mortality in tropical countries. Strategies are directed to combat malaria including development of diagnostic tools, serological markers and vaccinations. A target under intensive studies is Merozoite Surface Protein (MSP)-3. The aim of this study is to express and pur...
Source: Parasitology International - Category: Parasitology Source Type: research
Despite continuous efforts, the century-old goal of eradicating malaria still remains. Multiple control interventions need to be in place simultaneously to achieve this goal. In addition to effective control measures, drug therapies and insecticides, vaccines are critical to reduce mortality and morbidity. This has led to numerous studies investigating various malaria vaccine candidates, which are mostly subunit vaccines. However, they have shown limited efficacy in Phase II and III studies. To date, only whole parasite formulations have shown to induce sterile immunity in human. In this article, we review and discuss the ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
The Plasmodium falciparum Pfs230 and Pfs48/45 proteins are expressed during transmission from man to mosquito and are leading candidates for a malaria transmission blocking vaccine. Individually they generate transmission blocking (TB) antibodies in rodent models. Whether the single protein vaccines are suitable to use in field settings will primarily depend on their potency to elicit functional antibodies. We hypothesized that a combination of both proteins will be more potent than each protein individually. Therefore we designed chimeric proteins composed of fragments of both Pfs230 and Pfs48/45 as well as single protein...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Condition:   Malaria Interventions:   Biological: R21 Matrix-M vaccination;   Biological: R21 Matrix-M vaccination and CHMI Sponsor:   University of Oxford Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
How antibodies naturally acquired during Plasmodium falciparum infection provide clinical immunity to blood-stage malaria is unclear. We studied the function of natural killer (NK) cells in people living in a malaria-endemic region of Mali. Multi-parameter flow cytometry revealed a high proportion of adaptive NK cells, which are defined by the loss of transcription factor PLZF and Fc receptor -chain. Adaptive NK cells dominated antibody-dependent cellular cytotoxicity responses, and their frequency within total NK cells correlated with lower parasitemia and resistance to malaria. P. falciparum–infected RBCs induced N...
Source: The Journal of Experimental Medicine - Category: Internal Medicine Authors: Tags: Innate Immunity and Inflammation, Infectious Disease and Host Defense Brief Definitive Reports Source Type: research
The ability of a malaria antigen to induce effective, long-lasting immune responses is important for the development of a protective malaria vaccine. Plasmodium vivax merozoite surface protein-8 (PvMSP8) has been...
Source: Malaria Journal - Category: Infectious Diseases Authors: Tags: Research Source Type: research
More News: African Health | Children | Ghana Health | Infectious Diseases | Malaria | Malaria Vaccine | Vaccines